Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep;10(18):1014. doi: 10.21037/atm-22-4267

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2022 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

CD163⁺ TAMs exosomes can promote EMT, CSC characteristics, and MDR expression in EOC cells. (A-E) Expression of EMT transcription factors SNAIL1, ZEB1, and TWIST1 and the epithelial signature marker CHD1 (the gene encoding E-cadherin protein) after 72 h of treatment with CD163⁺ TAM exosomes also changes the expression of the mesothelial marker Vimentin. (F-H) Changes in the expression of CSC markers Nango, SOX2, and POU5F1. (I-K) Changes in the expression of MDR markers ABCB1, ABCG2 and ABCC1 (exo 100 µg, n=6). *, P<0.05; **, P<0.01; ***, P<0.001. CSC, cancer stem cell; DDP, cis-diamminedichloroplatinum; EMT, epithelial-mesenchymal transition; EOC, epithelial ovarian cancer; exo, exosomes; MDR, multidrug resistance; TAMs, tumor-associated macrophages.